
A Phase 3 Study Has Shown Encouraging Results for an Investigational Treatment for Dravet Syndrome
Zogenix, Inc has announced the top-line results from a Phase 3 study of the investigational drug ZX008 (low-dose fenfluramine hydrochloride) for the treatment of young patients with Dravet syndrome. The…